AC
AGIO icon

Armistice Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Armistice Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108M Buy
3,200,000
+200,000
+7% +$5.67M 1.93% 7
2025
Q4 		$81.7M Buy
3,000,000
+2,100,000
+233% +$73.7M 0.97% 14
2025
Q3 		$36.1M Buy
+900,000
New +$33.9M 0.54% 28

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital's AGIO Position: Q1 2026 in Review

Armistice Capital reduced its Agios Pharmaceuticals (AGIO) stake by 11% in Q1 2026, selling an estimated $9.07M and leaving 2,716,000 shares worth $91.9M. The position accounts for 1.63% of the portfolio, ranked #10.

Armistice Capital first reported a position in AGIO in Q3 2022 and has held it in 15 quarters since. The position peaked at $98.1M in Q3 2024. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Armistice Capital held 2,716,000 shares of Agios Pharmaceuticals worth $91.9M as of Q1 2026.
  • Armistice Capital sold 320,000 Agios Pharmaceuticals shares in Q1 2026, an estimated $9.07M.
  • Agios Pharmaceuticals made up 1.63% of Armistice Capital's portfolio in Q1 2026, its #10 holding.
  • Armistice Capital first reported a position in Agios Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Armistice Capital's Agios Pharmaceuticals position peaked at $98.1M in Q3 2024.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.